 |
 Video: What is a Stock Split?
|
|
|
| Protagonist Therapeutics is a clinical-stage biopharmaceutical company with various peptide-based new chemical entities in different stages of development, all derived from Co.'s proprietary technology platform. Co.'s clinical programs address two main categories of diseases; hematology and blood disorders, and inflammatory and immunomodulatory diseases. Co.'s main clinical asset, rusfertide (generic name for PTG-300) is an injectable hepcidin mimetic in development for the potential treatment of erythrocytosis, iron overload and other blood disorders. PN-943 is an investigational, orally delivered, gut-restricted alpha-4-beta-7 specific integrin antagonist for inflammatory bowel disease. According to our Protagonist Therapeutics stock split history records, Protagonist Therapeutics has had 0 splits. | |
|
Protagonist Therapeutics (PTGX) has 0 splits in our Protagonist Therapeutics stock split history database.
Looking at the Protagonist Therapeutics stock split history from start to finish, an original position size of 1000 shares would have turned into 1000 today. Below, we examine the compound annual growth rate — CAGR for short — of an investment into Protagonist Therapeutics shares, starting with a $10,000 purchase of PTGX, presented on a split-history-adjusted basis factoring in the complete Protagonist Therapeutics stock split history.
Growth of $10,000.00
Without Dividends Reinvested
|
| Start date: |
08/15/2016 |
|
| End date: |
04/24/2024 |
|
| Start price/share: |
$11.50 |
|
| End price/share: |
$25.70 |
|
| Dividends collected/share: |
$0.00 |
|
| Total return: |
123.48% |
|
| Average Annual Total Return: |
11.01% |
|
| Starting investment: |
$10,000.00 |
|
| Ending investment: |
$22,340.96 |
|
| Years: |
7.70 |
|
|
|
|
|
